Arrowstreet Capital
AKCA

Arrowstreet Capital’s Akcea Therapeutics Inc AKCA Stock Holding History

Arrowstreet Capital’s Portfolio AKCA Stock Details AKCA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q3 		– Sell
-27,451
Closed -$376K – 2635
2020
Q2 		$376K Buy
+27,451
New +$424K ﹤0.01% 2043

Other funds holding AKCA

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
GF
Gabelli Funds Rye, New York $14.8B AUM 32.24% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return
CS
Credit Suisse Zurich, Switzerland $104B AUM 34.76% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Arrowstreet Capital's AKCA Position: Q3 2020 in Review

Arrowstreet Capital sold out of Akcea Therapeutics Inc (AKCA) in Q3 2020, closing a stake of 27,451 shares — an estimated $376K sold.

Arrowstreet Capital first reported a position in AKCA in Q2 2020 and held it in 1 quarter. The position peaked at $376K in Q2 2020. 98 funds tracked by Wall St. Rank hold AKCA as of Q3 2020.

  • Arrowstreet Capital reported no remaining Akcea Therapeutics Inc position as of Q3 2020 after selling out during the quarter.
  • Arrowstreet Capital sold 27,451 Akcea Therapeutics Inc shares in Q3 2020, an estimated $376K.
  • Arrowstreet Capital first reported a position in Akcea Therapeutics Inc in Q2 2020 and held it in 1 quarter.
  • Arrowstreet Capital's Akcea Therapeutics Inc position peaked at $376K in Q2 2020.
  • 98 funds tracked by Wall St. Rank held Akcea Therapeutics Inc as of Q3 2020.

Based on Arrowstreet Capital's 13F filing for Q3 2020, filed 12 Nov 2020.